Bli medlem
Bli medlem

Du är här


Adaptimmune Therapeutics plc: Adaptimmune Announces New Additions to Manufacturing Senior Management

PHILADELPHIA and OXFORD, United Kingdom, Jan. 22, 2016 (GLOBE NEWSWIRE) --
Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR
engineered T-cell therapy to treat cancer, today announced that it has
augmented its manufacturing leadership to prepare for clinical and commercial
scale up with the additions of William Buecheler as Vice President,
Manufacturing Operations, and Phil Bassett as Head of Process Development.

Mr. Buecheler is responsible for Adaptimmune's global manufacturing
operations, including contract and in-house manufacturing activities, and is
leading the implementation of scale up plans designed to achieve commercial
manufacturing capability. Mr. Bassett is responsible for process development
activities including leading Adaptimmune's T-cell and lentivirus process

"Adaptimmune is in the midst of scaling up its manufacturing expertise, which
significantly enhances our ability to run multiple clinical studies of our
TCR therapies and, eventually, commercialize our products," said James Noble,
Chief Executive Officer. "As such, manufacturing excellence is key to our
long term success. Hiring the best in the field of manufacturing is critical
to us, and Bill and Phil are already making significant contributions."

Bill Buecheler brings to Adaptimmune over 25 years of industry experience in
manufacturing operations, facility planning and expansion, leadership of FDA
pre-approval inspection and document preparation, and manufacturing process
improvements. He joins Adaptimmune from Novartis Pharmaceuticals, where he
acted as the Director and Process Unit Head, with responsibility for overall
manufacturing operations of the Cell and Gene Therapy Process Unit. As a
member of the senior leadership team, his responsibilities included
manufacturing efforts to support the scale up operations for Novartis' CTL019
chimeric antigen receptor product for treatment of ALL and CLL patients.
Prior to joining Novartis, he worked and consulted for numerous
pharmaceutical and biotech companies in areas including facility build out
and expansion, change control, process improvement, cycle time reduction and
critical path project management. Mr. Buecheler earned his Master of Business
Administration degree from Syracuse University.

Phil Bassett brings with him over 15 years of process manufacturing experience
in CMO, small biotech and large biopharma environments. Most recently, Mr.
Bassett served as Head of Manufacturing Development for the Cell Therapy
Catapult, a UK-based Center of Excellence in cell therapy, where he was
responsible for technology transfer and providing late stage commercial
manufacturing, scale-up and process industrialization expertise. Prior to the
Cell Therapy Catapult, he served at UCB Celltech as the Associate Director
and Head of Fermentation Process Sciences, managing the upstream development
team working on clinical and commercial processes, and leading process
development, scale up and technology transfer efforts. He also spent several
years in roles of increasing responsibility with Cobra Biomanufacturing plc,
a UK-based international contract development and manufacturing organization
providing biologics for pre-clinical and clinical supply.

About Adaptimmune

Adaptimmune is a clinical stage biopharmaceutical company focused on novel
cancer immunotherapy products based on its T-cell receptor (TCR) platform.
Established in 2008, the company aims to utilize the body's own machinery -
the T-cell - to target and destroy cancer cells by using engineered,
increased affinity TCRs as a means of strengthening natural patient T-cell
responses. Adaptimmune's lead program is an affinity enhanced T-cell therapy
targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell
therapy has demonstrated signs of efficacy and tolerability in Phase 1/2
trials in solid tumors and in hematologic cancer types, including synovial
sarcoma and multiple myeloma. In June 2014, Adaptimmune announced that it had
entered into a strategic collaboration and licensing agreement with
GlaxoSmithKline (GSK) for the development and commercialization of the NY-ESO
TCR program in partnership with GSK. In addition, Adaptimmune has a number of
proprietary programs. The company has identified over 30 intracellular target
peptides preferentially expressed in cancer cells and is currently
progressing 12 through unpartnered research programs. Adaptimmune has over
200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For
more information:

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties. Such
risks and uncertainties could cause our actual results to differ materially
from those indicated by such forward-looking statements, and include, without
limitation: the success, cost and timing of our product development
activities and clinical trials and our ability to successfully advance our
TCR therapeutic candidates through the regulatory and commercialization
processes. For a further description of the risks and uncertainties that
could cause our actual results to differ materially from those expressed in
these forward-looking statements, as well as risks relating to our business
in general, we refer you to our Annual Report on Form 20-F filed with the
Securities and Exchange Commission on October 13, 2015. The forward-looking
statements contained in this press release speak only as of the date the
statements were made and we do not undertake any obligation to update such
forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contacts
Will Roberts
Vice President, Investor Relations
T: (215) 825-9306

Margaret Henry
Head of PR
T: +44 (0)1235 430036
Mob: +44 (0)7710 304249


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Adaptimmune Therapeutics plc via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.